PENTOXIFYLLINE tablet extended release

দেশ: মার্কিন যুক্তরাষ্ট্র

ভাষা: ইংরেজি

সূত্র: NLM (National Library of Medicine)

সক্রিয় উপাদান:

PENTOXIFYLLINE (UNII: SD6QCT3TSU) (PENTOXIFYLLINE - UNII:SD6QCT3TSU)

থেকে পাওয়া:

PD-Rx Pharmaceuticals, Inc.

INN (আন্তর্জাতিক নাম):

PENTOXIFYLLINE

রচনা:

PENTOXIFYLLINE 400 mg

প্রেসক্রিপশন টাইপ:

PRESCRIPTION DRUG

অনুমোদন অবস্থা:

Abbreviated New Drug Application

পণ্য বৈশিষ্ট্য

PENTOXIFYLLINE- PENTOXIFYLLINE TABLET, EXTENDED RELEASE
PD-RX PHARMACEUTICALS, INC.
----------
PENTOXIFYLLINE EXTENDED-RELEASE TABLETS, 400 MG
RX ONLY
DESCRIPTION
Pentoxifylline extended-release tablets for oral administration,
contains 400 mg of the active drug and
the following inactive ingredients: hydroxyethyl cellulose, isopropyl
alcohol, magnesium stearate,
povidone, and talc in an extended-release formulation. Pentoxifylline
is a tri-substituted xanthine
derivative designated chemically as
1-(5-oxohexyl)-3,7-dimethylxanthine that, unlike theophylline, is a
hemorrheologic agent, i.e. an agent that affects blood viscosity.
Pentoxifylline is soluble in water and
ethanol, and sparingly soluble in toluene.
The chemical structure is:
Molecular weight: 278.31
Molecular formula: C
H
N
O
CLINICAL PHARMACOLOGY
MODE OF ACTION
Pentoxifylline and its metabolites improve the flow properties of
blood by decreasing its viscosity. In
patients with chronic peripheral arterial disease, this increases
blood flow to the affected
microcirculation and enhances tissue oxygenation. The precise mode of
action of pentoxifylline and the
sequence of events leading to clinical improvement are still to be
defined. Pentoxifylline administration
has been shown to produce dose-related hemorrheologic effects,
lowering blood viscosity, and
improving erythrocyte flexibility. Leukocyte properties of
hemorrheologic importance have been
modified in animal and _in vitro_ human studies. Pentoxifylline has
been shown to increase leukocyte
deformability and to inhibit neutrophil adhesion and activation.
Tissue oxygen levels have been shown
to be significantly increased by therapeutic doses of pentoxifylline
in patients with peripheral arterial
disease.
PHARMACOKINETICS AND METABOLISM
After oral administration in aqueous solution pentoxifylline is almost
completely absorbed. It undergoes
a first-pass effect and the various metabolites appear in plasma very
soon after dosing. Peak plasma
levels of the parent compound and its metabolites are reached wi